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Despite the progress in effective treatments for HIV,
viral hepatitis, tuberculosis and sexually transmitted
infections (STIs), these infections remain major public
health concerns across Europe. Recurring challenges of
late presentation and unprioritized prevention pro-
grammes need to be effectively addressed in order to
control and prevent transmission and ensure that people
are diagnosed early and rapidly enter the care system.
The prevalence of co-infections is high due to the social
context of key populations and the shared modes of
transmission, varying with local epidemiology, which
underlines the need to combine efforts throughout the
continuum of care.
In its third Health Programme (2014–2020) the European
Commission endorsed and prioritized a cross-disease
integrated approach to combine efforts and promote cost-
effective, affordable and effective interventions. Infectious
diseases are generally managed in parallel structures with
disease specific policies and actions (e.g. the 2014–2016
Action Plan on HIV/AIDS) at both European and national
levels [1, 2]. In this framework, a three-year Joint Action on
integrating prevention, testing and linkage to care strategies
across HIV, viral hepatitis, TB and STIs in Europe (INTE
GRATE) was launched in Europe in 2017 [3, 4]. National
Ministries of health in 16 European Union (EU) and
neighbouring countries nominated 29 organisations (from
non-governmental institutions (NGOs) to public health
institutes and hospitals), to form a consortium focused on
the integration of early diagnosis and linkage to preven-
tion and care of HIV, viral hepatitis, TB and STIs.
The approach in INTEGRATE has been to explore
how effective tools for diagnosis and linkage to preven-
tion and care for one disease can be used for other dis-
eases; the applied methodology was to review existing
tools and then adapt and pilot these tools in other
disease areas (Fig. 1). A baseline survey was conducted
in late 2017 to map partner and country level testing
activities, monitoring and surveillance data collection,
treatment and linkage to care, prevention activities and
training needs.
The project built upon the experience and knowledge
of other European testing-oriented projects from
previous Health Programs such as HIV-COBATEST,
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Euro HIV EDAT and OptTEST, which had focussed pri-
marily on optimising testing for HIV, as well as the
EuroTEST initiative and its related projects [5–7].
INTEGRATE has been organised with 4 horizontal
and 4 core and complementary work packages (Fig. 2),
reflected in the different research articles presented in
this supplement. This article summarises the overall
main outcomes of the INTEGRATE project.
Integrated testing
An important focus area of INTEGRATE has been to in-
vestigate missed opportunities for combined testing for
HIV, viral hepatitis, STIs and - where relevant – TB.
Studies and testing services designed for HIV testing
have demonstrated the benefits of introducing a combin-
ation of tests for these infections depending on target
group and service set-up. Advances in HIV testing ap-
proaches have been explored to examine how they could
potentially be expanded to include testing for other dis-
eases and to evaluate their effectiveness. The European
Testing Week (ETW) [8] was expanded to also advocate
for raising testing awareness for viral hepatitis and STIs
and INTEGRATE successfully launched a pilot Spring
ETW that included viral hepatitis in May 2018 to com-
plement the original November campaign running since
2013 the week before World Aids Day (1 December).
The pilot observed an increase in the proportion of in-
volved organizations implementing combined activities
(targeting more than one disease) from 50% during the
previous November ETW in 2017 to 64% during the
pilot. Furthermore, the concept of testing guided by spe-
cific indicator conditions, as is the case for HIV, was ex-
panded to also include combined testing for HCV where
appropriate. Combined HIV and HCV testing was found
to be particularly feasible with high positivity rates
among people presenting with STIs and those attending
drug and alcohol management centres. The results of
these interventions are further described in article 2 [9]
and 3 [10]. At the policy level, this was supported by the
development of the first integrated testing guidance for
HIV and viral hepatitis, published by ECDC in Decem-
ber 2018 [11].
Since March 2020, many testing services have been af-
fected by the COVID-19 pandemic. As a consequence,
the Spring ETW in May 2020, focused on virtual activ-
ities and on the adaptations of testing services. So far,
Fig. 1 INTEGRATE review methodology. Existing effective tools for
diagnosis and linkage to prevention and care were reviewed,
adapted and piloted in other disease areas
Fig. 2 INTEGRATE Work Packages
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evidence shows a decline in the number of tests for in-
fectious diseases other than for SARS-CoV-2, both in
health care and community facilities [12, 13], which will
be extremely important to monitor in future.
The acceptability and usability of self-tests for HIV
was investigated in Lithuania and Italy respectively, and
presented in article 4 [14], showing that 75% of online
survey respondents in Lithuania stated they would likely
buy and use an HIV self-test in the future, citing confi-
dentiality, privacy and a rapid result as the main reasons,
while the most commonly cited barrier was price. In
Italy, 71% of first time HIV self-testers were satisfied
with their test experience and said they would use an
HIV self-test in the future: the most commonly cited
reason being a rapid result. As a diagnostic tool, self-
testing has the potential to reach people who might not
attend established services and it is a recommended
element in a testing strategy for key populations that
should undertake regular testing [15, 16]. However, self-
tests for HIV are regulated differently across Europe and
less than half of countries in Europe (47%, 15/32) have
fully implemented HIV self-testing and the price (Euros
20–25) remains a major barrier to access. Also, accord-
ing to UNAIDS Global AIDS Monitoring reporting from
10 countries in Europe, only around 40.000 kits have
been distributed by the public sector in 2019 [17]. Fur-
ther, self-tests for other infections are only now starting
to be considered, which is likely to represent a missed
opportunity for timely diagnosis and important individ-
ual and public health benefits of early treatment. A
number of usability, feasibility and acceptability studies
are underway on hepatitis C self-testing, led by the
Foundation for Innovative New Diagnostics [18] and
World Health Organisation with the aim to develop
guidance for implementation in early 2021, and with
great potential for further integration of testing for mul-
tiple diseases in the future.
Combination prevention
Article 5 [19] and 6 [20] present results from the INTE
GRATE workstream focused on partner notification and
the development of a web and mobile application
designed to enhance the effectiveness of combination
prevention by integrating HIV, hepatitis, STIs and TB in a
single user-friendly information and communications
technology (ICT) tool. For this purpose, a desk review was
conducted to map existing online tools, revealing that to
date most of them had been launched as disease specific
aids. In response, INTEGRATE developed the application
– “RiskRadar for HIV, hepatitis, STIs and TB” – the first
of its kind to provide integrated information, risk assess-
ment, test finders and an anonymous partner notification
service for all four disease areas. RiskRadar succeeded in
integrating prevention information and messages for
multiple diseases in one user-friendly tool available for
both android and iPhones, supporting ongoing efforts to
address missed opportunities for multiple disease messa-
ging and testing. It is presently available in four EU lan-
guages (Croatian, English, Italian and Lithuanian).
Article 6 [19] outlines the barriers and results on inte-
grating partner notification and contact tracing services
across Europe. The challenge of partner notification and
contract tracing is that they are under the governance of
different agencies in different countries, and indeed
different systems have been set up within countries, de-
pending on the local health authority. While there is
clear national guidance on contact tracing for tubercu-
losis in most EU countries, the situation is different for
the other infections – HIV, viral hepatitis and STIs.
Partner notification should be part of best practice for
all the conditions and ‘joined up’ pathways to care need
to be developed between the different hospital, public
health, and community agencies dealing with these
diseases.
In article 7 [21], results from a patient experience
survey undertaken in Romania and Spain among people
living with HIV is presented. Results show that while
health-related quality of life (HrQoL) was good overall
in a sample of people accessing HIV care, people with
HIV reported symptoms of anxiety/depression more fre-
quently than the general population in both countries.
Health concerns were highlighted as a key area of con-
cern for people with HIV, despite high levels of anti-
retro viral treatment coverage and adherence. Worse
HrQoL was more likely to be reported by people with
non-HIV related health conditions and financial instabil-
ity. This study highlights the importance of monitoring
HrQoLin people with HIV due to the chronic nature of
the disease. In this highly-treatment experienced group,
disparities were found, particularly highlighting mental
health as an area which needs more attention in order to
improve the well-being of people with HIV.
Integration of data sources
Although community-based testing for HIV as well as
for some other STIs and for hepatitis B and C has re-
cently increased in most European countries, in some
accounting for up 30% of reported new HIV cases, data
from these services are seldom included in national
monitoring and evaluation (M&E) information systems
and disease specific surveillance reports [22]. INTEGR
ATE addressed gaps in surveillance of national testing in
a workstream in collaboration with the European Centre
for Disease Prevention and Control (ECDC), highlighted
in article 8 [23] and 9 [24]. A minimum set of indicators
for community testing has been proposed for inclusion
in national surveillance and M&E systems through the
Dublin Declaration monitoring system in order to
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provide a better overview of progress and to monitor
effectiveness of different interventions [11, 22, 25].
Moreover, pilot studies aiming at increasing the integra-
tion of data derived from community testing into
national surveillance and M&E information systems
were implemented in Estonia, Latvia, Poland, Serbia,
Slovenia and Spain. Their results and recommendations
presented in this supplement and the experiences
described will support such data integration in other
European countries. ECDC included questions from the
minimum list of community M&E indicators into their
Dublin Declaration questionnaire 2020 to contribute to
evidence-based community testing policies in European
countries.
Country responses - how to foster collaborations
across diseases areas
Four national multi-stakeholder meetings were arranged
in 2019 (Rome, Italy; Vilnius, Lithuania; Warsaw, Poland
and Zagreb, Croatia) with the aim to foster cross-
disciplinary and cross-disease-area collaborations at the
national level. Results from these meetings are presented
in article 10 [26] and show how multi-stakeholder dis-
cussions and in-depth analysis of strategies to address
current gaps can foster synergies between stakeholders
and a common national effort to seek solutions. Meeting
outcomes raise awareness for how disease ‘silos’, often
reflecting the mandate of organisations, are hampering
synergies and implementation of integarted approaches.
On the ground, integration across diseases needs to
consider the different levels of the health system – and
the involvement of community-based programmes-
across the continuum of care, but it is often hindered by
practical challenges, local relationships, regulatory
frameworks and legal barriers. Nevertheless, the INTE
GRATE Joint Action has demonstrated that there is a
high level of support among national stakeholders across
Europe for improving the cross-disease integration of
HIV, hepatitis, STI and TB services. In many instances,
the participation in an EU co-funded Joint Action like
INTEGRATE, bringing national experts together with
agency representatives and international experts helped
improve collaborations between services and disease
areas, and resulted in better harmonization of services,
data collection and data sharing. Cross-border collabora-
tions such as INTEGRATE and the support from European
Union agencies such as the ECDC and EMCDDA are key
to enable the sharing of experiences, transfer lessons and
support or facilitate a change from the current siloed ap-
proach to an integrated one.
The need for integration has been further heightened
since the declaration of the COVID-19 pandemic in
March 2020. As the impact of the pandemic on the
testing for other infectious diseases becomes clearer, the
need for collaboration and integration, for making
different testing modalities (like self-testing and
community-based testing) available as well as the need
for establishing timely and sensible monitoring systems
to understand evaluate and improve the effectiveness of
HIV, viral hepatitis and STI strategies becomes increas-
ingly evident and a challenge for European Health
Services.
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